We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

44 hedge funds and large institutions have $7.51M invested in Clearside Biomedical in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 43 → 44 (+1)

0.04% more ownership

Funds ownership: 0.76% → 0.81% (+0.04%)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

7% less capital invested

Capital invested by funds: $8.09M → $7.51M (-$581K)

Holders
44
Holders Change
+1
Holders Change %
+2.33%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$460K
2
GCP
GSA Capital Partners
United Kingdom
+$275K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$46.7K
4
Stifel Financial
Stifel Financial
Missouri
+$13.2K
5
GWP
Gen-Wealth Partners
Michigan
+$8.28K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$145K
2
Renaissance Technologies
Renaissance Technologies
New York
-$47.9K
3
BCM
Bridgeway Capital Management
Texas
-$41.4K
4
UBS Group
UBS Group
Switzerland
-$24.4K
5
Prudential Financial
Prudential Financial
New Jersey
-$22.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.69M +$460K +37,097 +20%
CG
2
Carmignac Gestion
France
$1.21M – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$632K -$1.54K -124 -0.2%
BlackRock
4
BlackRock
New York
$500K -$145K -11,716 -22%
GCP
5
GSA Capital Partners
United Kingdom
$427K +$275K +22,129 +165%
Renaissance Technologies
6
Renaissance Technologies
New York
$397K -$47.9K -3,861 -10%
First Manhattan
7
First Manhattan
New York
$274K – – –
State Street
8
State Street
Massachusetts
$212K – – –
BCM
9
Bridgeway Capital Management
Texas
$164K -$41.4K -3,333 -20%
Northern Trust
10
Northern Trust
Illinois
$132K – – –
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$106K – – –
Morgan Stanley
12
Morgan Stanley
New York
$105K – – –
PNC Financial Services Group
13
PNC Financial Services Group
Pennsylvania
$86.3K – – –
BWM
14
Brown Wealth Management
Illinois
$80K – – –
NFC
15
Northeast Financial Consultants
Connecticut
$74.4K – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$71.7K +$46.7K +3,764 +170%
CAPTRUST Financial Advisors
17
CAPTRUST Financial Advisors
North Carolina
$69.6K – – –
Stifel Financial
18
Stifel Financial
Missouri
$32K +$13.2K +1,067 +67%
ISFAN
19
Investor's Fiduciary Advisor Network
Washington
$27K – – –
UBS Group
20
UBS Group
Switzerland
$26K -$24.4K -1,970 -48%
NDSI
21
Newman Dignan & Sheerar Inc
Rhode Island
$24.1K – – –
SF
22
Synovus Financial
Georgia
$24K – – –
PAS
23
PKS Advisory Services
New York
$19.6K – – –
WP
24
Westmount Partners
California
$18.7K – – –
Commonwealth Equity Services
25
Commonwealth Equity Services
Massachusetts
$18K – – –
1
2

CLSD Hedge Fund Activity: Q2 2025 in Review

44 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2025, worth a combined $7.51M — down 7.2% from $8.09M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CLSD positions and 5 closed out — a net gain of 1 holder — while 7 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $460K. The largest seller was BlackRock, cutting an estimated $145K.

  • 44 institutional investors held Clearside Biomedical (CLSD) as of Q2 2025, up from 43 in Q1 2025.
  • Funds reported $7.51M of Clearside Biomedical stock for Q2 2025, down 7.2% quarter-over-quarter.
  • 6 funds opened new Clearside Biomedical positions in Q2 2025 and 5 closed out, a net change of +1 holder.
  • The largest Clearside Biomedical buyer in Q2 2025 was Vanguard Group, an estimated $460K added.
  • The largest Clearside Biomedical seller in Q2 2025 was BlackRock, an estimated $145K sold.

Based on aggregated 13F filings for Q2 2025.